RxDoctor Payments Data

Eric Spohn

Psychiatric/Mental Health · Elkhart, INNPI 1104580711

Payments from drug & device makers

$2,010in general payments, 2019–2025

Across 96 payments — averaging $20.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$534
  • AbbVie$276
  • E.r. Squibb & Sons, L.L.C.$238
  • Teva Pharmaceuticals USA, Inc.$201
  • Sunovion Pharmaceuticals Inc.$141
  • Johnson & Johnson$125
  • plus $494 from 9 others

What the payments were for

  • Food & beverage$1,78589%
  • Education$22411%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,010 in reported general payments places this provider in the 75th percentile of 729 psychiatric/mental health providers in Indiana.

See all psychiatric/mental health providers in Indiana

Medicare billing

Part B allowed, 2024
$5,744
Medicare patients
42
Services billed
75

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate77$252,044
Invega TrinzaPaliperidone Palmitate16$127,797
IngrezzaValbenazine Tosylate15$120,702
VraylarCariprazine Hcl50$81,227
Abilify MaintenaAripiprazole23$58,598
RexultiBrexpiprazole26$37,636
LatudaLurasidone Hcl21$30,752
Paliperidone ErPaliperidone42$24,762
AristadaAripiprazole Lauroxil11$17,512
TrintellixVortioxetine Hydrobromide25$16,240
Aripiprazole114$13,794
BelsomraSuvorexant26$12,207
FetzimaLevomilnacipran Hcl20$9,997
Clozapine OdtClozapine11$7,201
Lurasidone Hcl35$6,244

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$125$379,84193 claims
Neurocrine Biosciences, Inc.Ingrezza$44$120,70215 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$95$96,23349 claims
AbbVieVraylar, Fetzima$276$91,22470 claims
Sunovion Pharmaceuticals Inc.Latuda$141$30,75221 claims
Alkermes, Inc.Aristada$123$17,51211 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$17$16,24025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 729 psychiatric/mental health providers in Indiana.

Other psychiatric/mental health in Elkhart

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →